Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).

开始日期2020-01-31

申办/合作机构

University of Kansas

[+1]

100 项与 INB-100 相关的临床结果

登录后查看更多信息

100 项与 INB-100 相关的转化医学

登录后查看更多信息

100 项与 INB-100 相关的专利（医药）

登录后查看更多信息

项与 INB-100 相关的文献（医药）

2014-12-01·Journal of cardiothoracic and vascular anesthesia4区 · 医学

Perioperative Goal-Directed Therapy

4区 · 医学

Review

作者: Waldron, Nathan H ; Gan, Tong J ; Miller, Timothy E

From the Department of Anesthesiology, Duke University, Durham, North Carolina. T.E.M. is a consultant for Edwards Lifesciences, Covidien, and Hospira. Research funding from Cheetah Medical and Retia Medical. T.J.G. is a consultant for Baxter, Edwards Life Science, Hospira and QRx. Research support from AcelRx, Cheetah, Covidien, Cubist, Deltex, Fresenius, Merck, Pacira and Premier. This work was supported solely by departmental funds. Address reprint requests to Tong J. Gan, MD, MHS, FRCA, Professor and Chairman, Department of Anesthesiology, Stony Brook University HSC Level 4, Rm 060 Stony Brook, NY 11794-8480 Tel: (631) 444-2979 Fax: (631) 444-2907 E-mail: tong.gan@ stonybrookmedicine.edu © 2014 Elsevier Inc. All rights reserved. 1053-0770/2601-0001$36.00/0 http://dx.doi.org/10.1053/j.jvca.2014.07.008

2011-12-12·The Journal of cell biology1区 · 生物学

Synergy between the ESCRT-III complex and Deltex defines a ligand-independent Notch signal

1区 · 生物学

Article

作者: Hori, Kazuya ; Artavanis-Tsakonas, Spyros ; Kirchhausen, Tom ; Sen, Anindya

The Notch signaling pathway defines a conserved mechanism that regulates cell fate decisions in metazoans. Signaling is modulated by a broad and multifaceted genetic circuitry, including members of the endocytic machinery. Several individual steps in the endocytic pathway have been linked to the positive or negative regulation of the Notch receptor. In seeking genetic elements involved in regulating the endosomal/lysosomal degradation of Notch, mediated by the molecular synergy between the ubiquitin ligase Deltex and Kurtz, the nonvisual β-arrestin in Drosophila, we identified Shrub, a core component of the ESCRT-III complex as a key modulator of this synergy. Shrub promotes the lysosomal degradation of the receptor by mediating its delivery into multivesicular bodies (MVBs). However, the interplay between Deltex, Kurtz, and Shrub can bypass this path, leading to the activation of the receptor. Our analysis shows that Shrub plays a pivotal rate-limiting step in late endosomal ligand-independent Notch activation, depending on the Deltex-dependent ubiquitinylation state of the receptor. This activation mode of the receptor emphasizes the complexity of Notch signal modulation in a cell and has significant implications for both development and disease.

2008-11-01·Developmental cell1区 · 生物学

Drosophila HOPS and AP-3 Complex Genes Are Required for a Deltex-Regulated Activation of Notch in the Endosomal Trafficking Pathway

1区 · 生物学

Article

作者: Sylvaine Clemence ; Emily Franklin ; Marian Wilkin ; Maiko Taniguchi-Kanai ; Pajaree Tongngok ; Kazuya Hori ; Kenta Yamada ; Martin Baron ; Nicole Gensch ; Masato Motoki ; Kenji Matsuno

DSL ligands promote proteolysis of the Notch receptor, to release active Notch intracellular domain (N(ICD)). Conversely, the E3 ubiquitin ligase Deltex can activate ligand-independent Notch proteolysis and signaling. Here we show that Deltex effects require endocytic trafficking by HOPS and AP-3 complexes. Our data suggest that Deltex shunts Notch into an endocytic pathway with two possible endpoints. If Notch transits into the lysosome lumen, it is degraded. However, if HOPS and AP-3 deliver Notch to the limiting membrane of the lysosome, degradation of the Notch extracellular domain allows subsequent Presenilin-mediated release of N(ICD). This model accounts for positive and negative regulatory effects of Deltex in vivo. Indeed, we uncover HOPS/AP-3 contributions to Notch signaling during Drosophila midline formation and neurogenesis. We discuss ways in which these endocytic pathways may modulate ligand-dependent and -independent events, as a mechanism that can potentiate Notch signaling or dampen noise in the signaling network.

115

项与 INB-100 相关的新闻（医药）

2024-10-30

·今日头条

超级抗癌战士γ-δT细胞横扫多种癌症！肝癌、肺癌等患者已获益

每个人的身体内部都隐藏着一种“神秘力量”，时刻保护着我们远离癌症，这就是人体的免疫防御系统中至关重要的免疫细胞——“杀手”T细胞！近10年，三大基于T细胞的免疫疗法CAR-T、TCR-T、TILs已全部“修成正果”，获得批准上市。通过“强化”自己的免疫细胞清除全身肿瘤的梦想已成为现实，这些处于临床实验及上市的全新疗法已经帮助了世界各地成千上万的肿瘤患者。近期，一项由美国知名的莫菲特癌症中心主导的研究登上了国际知名期刊《Cell Reports Medicine》杂志上，揭露了一种新型的免疫细胞γ-δT细胞在33种不同癌症类型中的重要作用！研究人员说，尽管γ-δT仅占 T 细胞群的一小部分，但 γδ T 细胞能够识别更广泛的肿瘤抗原。最近的突破性发现表明，可以通过靶向治疗方法增强或挽救 γδ T 细胞的抗肿瘤功效。目前研究人员已经对覆盖33 种癌症类型的 γδ TCR 景观进行最准确、最全面的检查，这意味着，这是迄今为止人类癌症上最大的 γδ 克隆集合，通过深入了解γ-δT细胞在不同类型癌症中的作用，能够更精准地定制治疗方案，以提高患者的治疗效果！值得振奋的是，目前国内以及国际上已成功采用γ-δT细胞治疗肝癌、肺癌、食管癌、白血病等各类癌症，并取得了鼓舞人心的初步数据！ “超级抗癌战士”--γ-δT细胞横空出世！按T细胞表面TCR的类型分为两类：由α链和β链组成TCR的T细胞被称为αβT细胞，由γ链和δ链组成的T细胞被称为γδT细胞。 γδT 细胞是胸腺中发育的第一个 T 细胞谱系，这种细胞大约在 40 年前首次被发现。γδT 细胞仅占循环 T 细胞群的 1-10%，早在孕龄 12.5 周时即可在人类中观察到。然而，这些细胞一旦产生，就会在胸腺外扩增和成熟，目前研究证实，γδ T 细胞生物学的许多方面似乎非常适合癌症免疫治疗，包括对肿瘤组织的趋向性、非常广泛的识别潜力、对正常组织的高耐受性以及功能多效性。 γδT细胞的六大功能 γδT细胞可以产生大量的细胞因子和趋化因子来调节其他免疫(如 Treg)和非免疫细胞 γδT细胞可以为 B 细胞提供帮助，诱导树突细胞(DC)成熟 γδT细胞参与巨噬细胞募集 γδT 细胞对各种恶性肿瘤(如神经母细胞瘤)表现出不同程度的细胞溶解活性 γδT 细胞产生维持表皮完整性的生长因子 γδT细胞可以为 αBT细胞提供抗原 γδT 细胞在免疫治疗中四大的优势 1. γδT 细胞通过产生和释放可溶性因子来靶向直接以及间接杀伤肿瘤细胞，是天然的肿瘤杀手； 2. 不受限于MHC分子的递呈机制，异体用于肿瘤临床治疗的安全性已经被多次验证； 3. 与通用型UCAR-T不同，同种异体γδ T细胞或新抗原γδ T细胞不需要利用基因编辑技术敲除TCR基因来减少免疫排斥，因此可避免脱靶等诸多风险； 4. 至今多篇研究均表明γδ T细胞具备了良好的肿瘤浸润能力，对于克服一般CAR-T疗法的实体瘤障碍（例如：TME）具有极高的潜在能力。横扫多种癌症！肝癌、肺癌、食管癌、白血病等患者已获益近年来，γδ-T细胞在感染免疫、肿瘤免疫、AID等领域中所起的作用越来越受到广泛关注。国内外学者就其作用特点与机制做了大量研究，发现γδT细胞能执行复杂的功能，如免疫监视、免疫调节和发挥免疫效应等作用。特别是γδ-T 细胞可用于异体治疗的特质及其在实体瘤治疗中展现出卓越的潜力！ 01 全球首次完成γδ-T细胞治疗晚期肝癌、肺癌的3年期随访中国暨南大学生物医学转化研究院研究团队早在2017年-2018年在全球范围内率先完成了异体γδ T细胞临床研究。这项研究累计400多次异体γδ T细胞人体回输，临床观察达到130多例，初步证明了安全性和对实体癌初步有效。截至2021年9月，对8例晚期肝癌和10例晚期肺癌患者(接受细胞治疗次数均在5次或以上)进行了随访，从他们第一次输注异体γδ-T 细胞开始，目前这些患者的生存时间中位数为42.4个月(范围为30-50个月)！幸运的是，一位参加临床试验的胆管癌（IV 期）患者，之前接受了肝移植，随后出现了复发性纵隔淋巴结转移，在接受同种异体 γδ T 细胞治疗，积极调节患者的外周免疫功能，消除肿瘤活性，改善生活质量，延长患者寿命。经过 8 次 γδ T 细胞治疗后，他的淋巴结大小显著减小，活性降低，得到了完全控制。值得一提的是，这是全球首次完成对接受异体γδ-T细胞治疗晚期肝癌、肺癌的3年期随访。在国际上，率先证明同种异体γδ T细胞治疗在临床使用的安全性，对肝癌与肺癌展示了初步有效，并显著改善晚期肿瘤患者生活质量与免疫状态。 02 过继性γδT细胞移植单独或联合化疗治疗晚期食管癌 2021年，日本东京大学医院发表了一项在使用铂类、5-氟尿嘧啶和紫杉烷治疗后，复发性或转移性食管癌 (r/mEC) 患者中接受过继性 γδT 细胞疗法的 1 期试验结果。结果显示，26 名患者接受了 γδT 单药治疗。γδT 细胞治疗未发生严重不良事件。中位总生存期为 5.7 个月，中位无进展生存期为 2.4 个月。18 名患者接受了化疗联合γδT细胞。中位总生存期为 13.4 个月，中位无进展生存期为 4.0 个月。客观缓解率和疾病控制率分别为 39% 和 78%。研究人员认为，对于复发性或转移性食管癌患者，无论是否联合化疗，使用 γδT 细胞免疫疗法都是安全可行的。γδT 细胞联合化疗观察到了生存益处。 03 100%患者肿瘤细胞消退1年！γ-δT细胞为白血病带来新生机 2024年6月13日，在第49届欧洲血液学协会（EHA）年会上，公布了一款名为“INB-100”的抗癌新星γδ T细胞治疗的卓越临床数据，全部入组患者在接受γδ T细胞治疗后均，缓解率高达100%，且完全完全缓解状态持续长达1年之久！而既往接受造血干细胞移植等传统治疗的患者，一年内的率则高达50%。更为惊喜的是，其中3例高危白血病患者已经无癌生存35个月以上（近3年）！本研究首次证明了单倍体匹配同种异体或供体衍生细胞治疗，在365周的内部持续性和持久性！为高危或阻断性AML和其他血液系统恶性肿瘤患者提供了持久的无稳定性生存期，这对恶性肿瘤患者而言，无疑是巨大的福音。免疫疗法遍地开花！有望成为战胜癌症的终极武器！近年来，细胞治疗为恶性肿瘤、某些传染病和遗传病等难治性疾病患者带来了新的希望，并在美欧日等发达国家以多种方式开始进入临床应用，我国医疗机构也开展了大量临床研究，患者希望接受高质量细胞治疗的呼声日益增高。政府也在规范并加快细胞治疗科学发展，并允许临床研究证明安全有效的体细胞治疗项目经过备案在相关医疗机构进入转化应用，相关的临床试验也正在开展。 γ・ΔT细胞作为细胞毒性T细胞的另一个类型，是攻击癌细胞的另一个主要力量，成熟的细胞毒性T细胞受抗原刺激后，分化为效应细胞毒性T细胞和记忆细胞毒性T细胞。前者能特异性杀伤带抗原的靶细胞，如移植细胞、肿瘤细胞及受微生物感染的细胞等。γ・ΔT细胞用于以肺癌和多发性骨髓瘤为首的各种各样的癌症。中国，日本，美国等多家权威医院进行了临床研究，成果作为论文已经发表在国际期刊，是一种值得期待的治疗方法。想寻求γδT细胞等新一代新兴抗癌新帮助的病友，可将病历提交至全球肿瘤医生网医学部进行初步评估或申请免疫专家会诊。同时需要提醒病友，肿瘤的治疗一定是依托于权威医院及权威专家的正规治疗，在采取常规治疗手段（手术、放疗、化疗）治疗后，根据自身的经济情况，辅助免疫治疗技术等综合疗法，达到巩固治疗，预防复发，提高生活治疗，延长生存期的目的，最终取得抗癌成功。如果大家想全面了解自身的免疫状态或相关的免疫疗法，请致电医学部或加入免疫治疗医患交流群。

细胞疗法免疫疗法

2024-10-01

·GlobeNewswire-Health Care

IN8bio Announces Pricing of $12.4 Million Private Placement

Cash position now expected to fund current operating plan into 2026 Financing provides cash runway to advance the ongoing expansion cohorts in the Phase 1 trial of INB-100 for patients with Acute Myeloid Leukemia (AML) NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that it has entered into a definitive securities purchase agreement with accredited investors for a private placement that is expected to result in gross proceeds of approximately $12.4 million to IN8bio, before deducting placement agent fees and other offering expenses. The net proceeds from this financing are expected to fund the Company’s current operating plan into 2026. The private placement was led by an existing healthcare-focused institutional investor and included a large mutual fund company and other existing and new institutional investors. Under the terms of the securities purchase agreement, the Company will sell units comprised of an aggregate of 25,759,595 shares of the Company’s common stock, par value $0.0001 per share, pre-funded warrants to purchase 5,646,853 shares of common stock and warrants to purchase up to 31,406,448 shares of common stock (the “Series C Warrants”). The units will be sold at a purchase price of $0.395 per unit (or $0.3949 per unit with respect to units that include pre-funded warrants in lieu of common stock). The pre-funded warrants will have an exercise price of $0.0001 per share. The Series C Warrants will have an exercise price of $0.27 per share. IN8bio intends to use the net proceeds from the private placement to fund the clinical development of INB-100 and future product candidates and for working capital and other general corporate purposes. The proceeds will support the continued enrollment of patients in the expansion cohort with a new target total enrollment of approximately 25 patients at the recommended Phase 2 dose. IN8bio expects to complete this additional enrollment in the first half of 2025, with long-term follow-up results anticipated in late 2025 and in 2026. To affirm the improvements in relapse free and overall survival observed to date and to further de-risk a future registrational randomized control trial, IN8bio will also seek to add a parallel control cohort to prospectively assess leukemia patients and enable comparison between patients receiving INB-100 to those who only receive standard haplotransplantation. The closing of the private placement is subject to customary closing conditions and is expected to occur on or about October 4, 2024. Newbridge Securities Corporation acted as the sole placement agent for the private placement. The offer and sale of the foregoing securities is being made in a private placement pursuant to an exemption under the Securities Act of 1933, as amended (the “Securities Act”), and the Securities have not been registered under the Securities Act or applicable state securities laws. The Securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the Securities, nor shall there be any sale of the Securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About IN8bio IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-100, is focused on AML evaluating haplo-matched allogenic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma. Forward Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the completion of the offering, the satisfaction of customary closing conditions relating to the private placement, the use of the net proceeds in this private placement, IN8bio’s ability to achieve anticipated milestones, including the completion of enrollment of additional patients and data readouts in the INB-100 trial, IN8bio’s ability to add a parallel control cohort to the INB-100 trial, and IN8bio’s cash runway. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: the uncertainties related to market and other conditions and the completion of the public offering; risks to patient enrollment and follow-up, as well as IN8bio’s ability to meet anticipated deadlines and milestones; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements. These and other factors are described in greater detail in the section entitled “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 8, 2024, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Investors and Corporate Contact:Glenn Schulman, PharmD, MPHIN8bio, Inc. 203.494.7411gdschulman@IN8bio.com Patrick McCallIN8bio, Inc.646.933.5603pfmccall@IN8bio.com Media Contact:Kimberly HaKKH Advisors 917.291.5744Kimberly.ha@kkhadvisors.com

细胞疗法免疫疗法临床1期

2024-09-13

·药渡

裁员近半！一家生物科技公司的自然消亡

9月4日，IN8bio在提交给美国证券交易委员会的文件中表示，其正在纽约市和阿拉巴马州伯明翰的工厂裁减约49%的员工。同时，在执行管理团队和公司董事会实施11%的现金薪酬削减计划，以保留其现金资源，优化资源配置。 IN8bio预计与此次裁员相关的一次性成本约为30万美元，其中几乎全部都是与遣散费相关的现金支出，这些成本将在2024年第三季度发生。 IN8bio是一家临床阶段生物制药公司，专注于发现、开发和商业化用于实体瘤和血液瘤的γ-δ T细胞疗法。当前该公司的管线包括：用于治疗恶性胶质母细胞瘤 (GMB)的INB-200、INB-400和用于治疗治疗白血病的INB-400等。 IN8bio 现有管线，数据来源：IN8bio 官网据IN8bio 2024年上半年财报显示：上半年，IN8bio 累计净亏损额为1720万美元；截至6月30日，公司现金流仅为1020万美元。另外，IN8bio 还在提交给美国证券交易委员会的文件中称，公司将进行管道优先级排序，包括将专注于INB-100；暂停两项胶质母细胞瘤（GBM）项目INB-200和INB-400，停止INB-200的开发，暂停INB-400的患者入组，只继续对INB-200 1期临床和INB-400 2期临床的参与者进行监测。另外，该公司将探索实体瘤项目的潜在合作机会。其中，INB-200已完成患者治疗，最多重复六次给药；去年4月，INB-400被FDA授予了孤儿药称号，这是第一个获得FDA该称号的转基因γδT细胞疗法。而将重点关注的INB-100是一款来自健康供体的同种异体γδ T细胞，在体外经过扩增和激活后，被输注到白血病患者体内。在2023年欧洲血液与骨髓移植学会年会上，IN8bio宣布其INB-100在1期临床中，实现了100%的完全缓解（CR）。此外，迄今为止，INB-100两项试验的患者都超过了预期的无进展生存期（PFS）；截至2024年8月1日，自美国临床肿瘤学会（ASCO）和欧洲血液学协会（EHA）年会提供的临床更新以来，尚未报告新的复发病例。为了证实观察到的无复发生存期和总生存期的改善，并进一步降低未来注册随机对照试验的风险，IN8bio将寻求增加一个对照组，对白血病患者进行前瞻性评估，并对接受INB-100治疗的患者与只接受标准单倍体移植的患者进行比较。而预期的临床成本节约及裁员就是为了扩充现金流，实现以上计划。值得注意的是，在文件中，IN8bio称：“如果无法及时获得额外资本，或者根本无法获得额外资金，公司将不得不大幅推迟、缩减或停止其研发计划。如果公司无法继续作为一家持续经营的企业，它可能不得不终止其业务并处置其资产，其实现的价值可能大大低于其简明财务报表中所列的价值。” 2023年12月，IN8bio还与若干以医疗保健为重点的机构投资者签订了一份证券购买协议，完成了4690万美元的私募融资。参考资料来源： https://www.biospace.com/job-trends/in8bio-to-lay-off-about-49-of-employees https://investors.in8bio.com/news-releases/news-release-details/in8bio-announces-clinical-pipeline-prioritization-focus-inb-100 来源： MedTrend医趋势药渡媒体商务合作媒体公关 | 新闻&会议发稿张经理：18600036371（微信同号）点击下方“药渡“，关注更多精彩内容免责声明 “药渡”公众号所转载该篇文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请及时告知，我们会在24小时内删除相关信息。微信公众号的推送规则又双叒叕改啦，如果您不点个“在看”或者没设为"星标"，我们可能就消散在茫茫文海之中~点这里，千万不要错过药渡的最新消息哦！👇👇👇

临床1期财报ASCO会议孤儿药细胞疗法

100 项与 INB-100 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性淋巴细胞白血病	临床1期	美国	IN8bio, Inc.	2020-01-31
急性淋巴细胞白血病	临床1期	美国	University of Kansas	2020-01-31
急性髓性白血病	临床1期	美国	University of Kansas	2020-01-31
急性髓性白血病	临床1期	美国	IN8bio, Inc.	2020-01-31
骨髓增生异常综合征	临床1期	美国	IN8bio, Inc.	2020-01-31
骨髓增生异常综合征	临床1期	美国	University of Kansas	2020-01-31
费城染色体阳性慢性粒细胞白血病	临床1期	美国	University of Kansas	2020-01-31
费城染色体阳性慢性粒细胞白血病	临床1期	美国	IN8bio, Inc.	2020-01-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03533816 (GlobeNewswire) 人工标引	临床1期	白血病	10	INB-100	製憲壓壓積鏇鏇襯鬱範(築膚窪廠鏇願選鹹遞膚) = 顧糧遞顧觸選繭醖築窪鹹糧壓繭艱鏇鹹獵糧簾 (蓋糧糧鑰壓鏇艱網淵願 ) 更多	积极	2024-06-13
NCT03533816 (ASH2023) 人工标引	临床1期	白血病	10	INB-100	繭糧壓艱範築窪顧顧選(淵鹹襯廠積夢網顧鹽膚) = transient WBC and ANC decreases (100% each), platelet count decrease and anemia (88.9% each) and maculopapular rash, hypomagnesemia and blood creatine increased (55.6% each) 膚淵觸壓窪製顧積網憲 (艱觸積淵廠願窪獵鏇願 ) 更多	积极	2023-12-11
NCT03533816 (P134 INB-100, EBMT2023)	临床1期	-	10	INB-100	網鏇構鏇艱蓋廠鬱繭觸(憲鏇窪遞襯顧積鏇艱襯) = toxicities include CMV reactivation 艱襯憲壓憲網選淵顧積 (糧衊築壓憲壓鑰衊觸範 ) 更多	积极	2023-04-23
NCT03533816 (Corporate Publications) 人工标引	临床1期	急性髓性白血病	3	INB-100	構遞齋衊築糧鹽淵憲遞(齋鹽壓壓憲夢獵鬱蓋憲) = 製襯窪鬱齋襯蓋醖壓夢憲鬱繭製觸餘積範齋鏇 (網簾繭顧鏇遞積觸醖艱 ) 更多	积极	2022-07-27